Latest On Iterum Therapeutics plc (ITRM):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 10:43 EST | News | Iterum Therapeutics Non-GAAP EPS of -$0.58 | N/A |  |
| 2023-03-16 19:24 EST | News | Iterum Therapeutics Non-GAAP EPS of -$0.52 beats by $0.63 | N/A | |
| 2023-03-16 19:24 EST | News | Iterum Therapeutics plc (ITRM) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-16 04:01 EST | News | Iterum Therapeutics Q4 2022 Earnings Preview | N/A | |
| 2022-12-15 11:13 EST | News | Iterum Therapeutics rises 21% on U.S. patent covering oral sulopenem | N/A | |
About Iterum Therapeutics plc (ITRM):
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
General
- Name Iterum Therapeutics plc
- Symbol ITRM
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 44
- Fiscal Year EndDecember
- IPO Date2018-05-25
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.iterumtx.com
Valuation
- Price/Sales (Trailing 12 Mt.) 1349.79
- Enterprise Value Revenue 105.22
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.34
- Next Year EPS Estimate -$0.36
- Next Quarter EPS Estimate -$0.19
- Return on Assets -69%
- Earnings Per Share -$7.05
- Revenue Per Share $0
- Gross Profit 37000
- Quarterly Earnings Growth -100%
Highlights
- Market Capitalization 291.19 million
- EBITDA -96628000
- Analyst Target Price $2.25
- Book Value Per Share $1.71
Share Statistics
- Shares Outstanding 176.48 million
- Shares Float 175.79 million
- % Held by Insiders 115%
- % Held by Institutions 34.21%
- Shares Short 3.63 million
- Shares Short Prior Month 3.8 million
- Short Ratio 0.08
- Short % of Float 3%
- Short % of Shares Outstanding 2%
Technicals
- Beta 1.4
- 52 Week High $4.7
- 52 Week Low $0.45
- 50 Day Moving Average 1.72
- 200 Day Moving Average 1.07
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Iterum Therapeutics plc (ITRM) Dividend Calendar:
Iterum Therapeutics plc (ITRM) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Iterum Therapeutics plc (ITRM) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 9.74 million | 20.88 million |
| Income Before Tax | N/A | N/A | N/A | -15.98 million | -23.59 million |
| Selling General Administrative | N/A | N/A | N/A | 3.15 million | 2.3 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | N/A | N/A | -13.34 million | -23.18 million |
| Operating Income | N/A | N/A | N/A | -12.89 million | -23.18 million |
| Income Tax Expense | 24000 | 420000 | 178000 | N/A | 49000 |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | -489000 | -414000 |
| Net Income From Continuing Operations | N/A | N/A | N/A | -16.1 million | -23.64 million |
| Net Income Applicable to Common Shares | -11.19 million | -12.2 million | -12.52 million | N/A | -23.64 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | -2000 | N/A | N/A | 25000 |
| Change to Liabilities | -1.84 million | N/A | N/A | N/A | 4.37 million |
| Total Cash Flow from Investing Activities | -9000 | N/A | N/A | N/A | 25000 |
| Net Borrowings | -1.55 million | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | 767000 | 2.71 million | 45.87 million | N/A | 3.04 million |
| Change to Operating Activities | N/A | N/A | N/A | N/A | 902000 |
| Change in Cash | -3.66 million | -10.99 million | 18.46 million | N/A | -22.36 million |
| Total Cash from Operating Activities | -4.42 million | -13.69 million | -27.39 million | N/A | -25.41 million |
| Depreciation | 3.14 million | 39000 | 39000 | N/A | 39000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | 44.7 million | N/A | N/A | N/A | N/A |
| Change to Net Income | 2.7 million | N/A | N/A | N/A | 533000 |
| Capital Expenditures | 9000 | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 83.35 million | N/A | N/A | 84.05 million | 51.99 million |
| Total Stockholder Equity | -50.56 million | N/A | N/A | -41.74 million | -26.24 million |
| Other Current Liabilities | 3.71 million | N/A | N/A | 28.31 million | N/A |
| Total Assets | 32.79 million | N/A | N/A | 42.31 million | 25.75 million |
| Common Stock | 494000 | -55903000 | -48789000 | N/A | -26238000 |
| Other Current Assets | 6.96 million | N/A | N/A | N/A | N/A |
| Retained Earnings | -286.93 million | N/A | N/A | -251.02 million | N/A |
| Other Liabilities | 47.5 million | 48.03 million | 22.35 million | N/A | 44.36 million |
| Other Assets | 18.28 million | 17.7 million | 19.44 million | N/A | 20.95 million |
| Cash | 14.51 million | N/A | N/A | 23.26 million | 4.8 million |
| Total Current Liabilities | 41.7 million | N/A | N/A | 47.09 million | N/A |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 421000 | N/A | N/A | N/A | N/A |
| Total Current Assets | 21.47 million | 8.57 million | N/A | 28.62 million | 4.8 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -50.56 million | -55.9 million | -48.79 million | N/A | -26.24 million |
| Short Term Investments | N/A | N/A | N/A | 1.21 million | N/A |
| Long Term Debt | 22.46 million | N/A | N/A | 29.81 million | 7.63 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.75 million | N/A | N/A | 6.3 million | N/A |
Iterum Therapeutics plc (ITRM) Chart:
Iterum Therapeutics plc (ITRM) News:
Below you will find a list of latest news for Iterum Therapeutics plc (ITRM) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Iterum Therapeutics plc (ITRM) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Iterum Therapeutics plc (ITRM) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-02 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-29 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-10-28 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-27 | 8-K (Current report) | |
| 2020-10-26 | 424B4 (Prospectus [Rule 424(b)(4)]) | |
| 2020-10-22 | S-1/A (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-22 | S-1MEF (Registration adding securities to prior Form S-1 registration [Rule 462(b)]) | |
| 2020-10-22 | EFFECT (Notice of Effectiveness) | |
| 2020-10-21 | S-1/A (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-09 | S-1 (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-07 | 424B1 (Prospectus [Rule 424(b)(1)]) | |
| 2020-10-06 | EFFECT (Notice of Effectiveness) | |
| 2020-10-05 | S-1/A (General form for registration of securities under the Securities Act of 1933) | |
| 2020-10-05 | CORRESP (Correspondence) | |
| 2020-10-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-30 | 8-K (Current report) | |
| 2020-09-28 | UPLOAD (SEC-generated letter) | |
| 2020-09-25 | 8-K (Current report) | |
| 2020-09-22 | S-1 (General form for registration of securities under the Securities Act of 1933) | |
| 2020-09-02 | 8-K/A (Current report) | |
Iterum Therapeutics plc (ITRM) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Iterum Therapeutics plc (ITRM). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 115%
Institutional Ownership: 3421%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-27 | Michael W. Dunne | Chief Scientific Officer | Buy | 61,540.00 | 209,498.00 | | ||
| 2020-09-30 | Judith M. Matthews | Chief Financial Officer | Sell | 56,130.00 | 1.64 | 92,053.20 | 0.00 | |
| 2020-07-01 | Mark Chin | Director | Buy | 5,703.00 | 11,857.00 | | ||
| 2020-07-01 | RONALD HUNT | Director | Buy | 5,703.00 | 5,703.00 | | ||
| 2020-07-01 | Patrick J Heron | Director | Buy | 2,852.00 | 9,006.00 | | ||
| 2020-06-13 | David George Kelly | Director | Buy | 11,406.00 | 37,108.00 | | ||
| 2020-06-02 | Sofinnova Venture Partners IX, L.P. | 10% Share Holder | Sell | 400,000.00 | 1.61 | 642,960.00 | 1,226,514.00 | |
| 2020-06-01 | Sofinnova Venture Partners IX, L.P. | 10% Share Holder | Sell | 100,000.00 | 1.69 | 169,120.00 | 1,626,514.00 | |
| 2019-05-24 | David George Kelly | Director | Buy | 6,154.00 | 25,702.00 | | ||
| 2019-05-24 | Paul R Edick | Director | Buy | 6,154.00 | 31,390.00 | | ||
| 2019-05-24 | Brenton Karl Ahrens | Director | Buy | 6,154.00 | 6,154.00 | | ||
| 2019-05-24 | JAMES HEALY | Director | Buy | 6,154.00 | 6,154.00 | | ||
| 2019-05-24 | Mark Chin | Director | Buy | 6,154.00 | 6,154.00 | | ||
| 2019-05-24 | Patrick J Heron | Director | Buy | 6,154.00 | 6,154.00 | | ||
| 2018-11-30 | David George Kelly | Director | Buy | 10,000.00 | 6.29 | 62,887.00 | 19,548.00 | |
| 2018-10-30 | Mark Chin | Director | Buy | 58,000.00 | 6.10 | 353,800.00 | 1,089,903.00 | |
| 2018-09-04 | Michael W. Dunne | Chief Scientific Officer | Buy | 500.00 | 10.00 | 5,000.00 | 147,958.00 | |
| 2018-08-27 | Michael W. Dunne | Chief Scientific Officer | Buy | 500.00 | 10.00 | 5,000.00 | 147,458.00 | |
| 2018-08-24 | Michael W. Dunne | Chief Scientific Officer | Buy | 500.00 | 10.00 | 5,000.00 | 146,958.00 | |
| 2018-08-23 | Paul R Edick | Director | Buy | 500.00 | 10.44 | 5,218.70 | 25,236.00 | |